GoAI
Get started
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc.

PHAT

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$8.7646

−$0.1054 · -1.19%

Aug 24, 11:17 AM ET

PHAT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

63

Gaining

Sentiment

54

Mixed

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Steven L. Basta
Listed since
Oct 25, 2019
Employees
371

Market position

Day range

Current $8.7646

52-week range

Current $8.7646

Open
$8.88
Previous close
$8.87
Volume
217.9K
0.16× average
Average volume
1.33M
Average daily volume
Market cap
709.06M USD
Beta
0.5
Market reference 1
50-day average
$10.3521
-15.34% below average
200-day average
$12.314
-28.82% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-6.85×
P/B (TTM)
-2.13×
P/S (TTM)
2.96×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
82.92%
Operating margin
-16.96%
Net margin
-41.34%

Financial health

Debt / equity
-0.49×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3052%-8807%-20665%-32524%Gross margin, FY2023: 75.51%Gross margin, FY2024: 85.57%Gross margin, FY2025: 87.09%Operating margin, FY2023: -24532.55%Operating margin, FY2024: -502.18%Operating margin, FY2025: -91.36%Net margin, FY2023: -29558.94%Net margin, FY2024: -605.09%Net margin, FY2025: -126.35%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 75.51%. Gross margin FY2024 85.57%. Gross margin FY2025 87.09%. Operating margin FY2023 -24532.55%. Operating margin FY2024 -502.18%. Operating margin FY2025 -91.36%. Net margin FY2023 -29558.94%. Net margin FY2024 -605.09%. Net margin FY2025 -126.35%.

Income trends

Revenue

175.11M USD+216.93%

Operating income

−159.99M USD+42.34%

Net income

−221.25M USD+33.82%
Income trends across reported periods226.05M USD22.28M USD−181.5M USD−385.27M USDRevenue, FY2023: 682K USDRevenue, FY2024: 55.25M USDRevenue, FY2025: 175.11M USDOperating income, FY2021: −135.08M USDOperating income, FY2022: −172.44M USDOperating income, FY2023: −167.31M USDOperating income, FY2024: −277.47M USDOperating income, FY2025: −159.99M USDNet income, FY2021: −143.88M USDNet income, FY2022: −197.72M USDNet income, FY2023: −201.59M USDNet income, FY2024: −334.33M USDNet income, FY2025: −221.25M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 682K USD. Revenue FY2024 55.25M USD. Revenue FY2025 175.11M USD. Operating income FY2021 −135.08M USD. Operating income FY2022 −172.44M USD. Operating income FY2023 −167.31M USD. Operating income FY2024 −277.47M USD. Operating income FY2025 −159.99M USD. Net income FY2021 −143.88M USD. Net income FY2022 −197.72M USD. Net income FY2023 −201.59M USD. Net income FY2024 −334.33M USD. Net income FY2025 −221.25M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue175.11M USD55.25M USD682K USD——
Cost of goods sold22.6M USD7.97M USD167K USD620K USD521K USD
Gross profit152.51M USD47.28M USD515K USD−620K USD−521K USD
Research and development32.78M USD34.08M USD49.9M USD71.44M USD72.34M USD
Selling, general, and administrative279.72M USD290.66M USD117.93M USD100.38M USD62.22M USD
Operating expenses312.5M USD324.75M USD167.83M USD171.82M USD134.56M USD
Interest income7.04M USD15.16M USD7.88M USD2.13M USD41K USD
Interest expense68.12M USD72.01M USD41.97M USD27.31M USD6.79M USD
Depreciation and amortization633K USD795K USD575K USD620K USD521K USD
Operating income−159.99M USD−277.47M USD−167.31M USD−172.44M USD−135.08M USD
Net income−221.25M USD−334.33M USD−201.59M USD−197.72M USD−143.88M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

6 institutions

PHAT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding PHAT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
17.57M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.77-0.39%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
11.11M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.29-0.56%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
5.14M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.62-0.78%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
4.41M
Weight
0.79%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.435-0.50%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
3.72M
Weight
0.03%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$211.48-0.97%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.93M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.36-0.20%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
2.41M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.6-0.54%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
2.21M
Weight
2.60%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.80-0.09%

Continue in GoAI

Research PHAT

research.disclaimer